Ernexa Therapeutics Inc.
ERNA
$1.47
-$0.02-1.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.94% | -17.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.39% | 1.19% | |||
| Operating Income | 8.39% | -1.22% | |||
| Income Before Tax | 61.73% | -42.55% | |||
| Income Tax Expenses | -62.50% | -27.27% | |||
| Earnings from Continuing Operations | 61.73% | -42.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 61.73% | -42.42% | |||
| EBIT | 8.39% | -1.22% | |||
| EBITDA | 8.41% | -1.27% | |||
| EPS Basic | 73.65% | -2.23% | |||
| Normalized Basic EPS | 73.71% | 12.93% | |||
| EPS Diluted | 73.65% | -2.23% | |||
| Normalized Diluted EPS | 73.71% | 12.93% | |||
| Average Basic Shares Outstanding | 45.58% | 39.11% | |||
| Average Diluted Shares Outstanding | 45.58% | 39.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||